Pathology of persistent thrombocytosis (>450 x 109/l) that is not reactive or attributable to another myeloproliferative neoplasm or myelodysplasia must be considered.
The aetiology of persistent thrombocytosis is unknown, though around 50% of cases have been seen to possess a JAK-2 mutation. This is not associated with radiation, drugs, or chemicals.
Complications to be aware of include the risk of transformation to myelofibrosis or acute myeloid leukaemia (AML), although this is less likely than in polycythaemia vera (PV).
The prognosis for individuals with persistent thrombocytosis is near normal life expectancy.
Join Shiken For FREEJoin For FREE